Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of Radium-223 in Biochemically Recurrent Prostate Cancer
NCT04206319Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2020
- Primary completion
- Feb 2026
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of radium-223 dichloride in prostate cancer (PCa), sponsored by National Cancer Institute. Primary endpoint: Changes in immune cell populations at 6 months. Started Sep 2020; status: active, not recruiting.
02
Drugs
radium-223 dichloride
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04206319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04206319.